-
Professor Niu Ting: Progress in the diagnosis and treatment of diffuse large B-cell lymphoma
Time of Update: 2021-06-11
At this meeting, Professor Niu Ting from West China Hospital of Sichuan University gave a theme report on "Diffuse Large B-Cell Lymphoma (DLBCL) Diagnosis and Treatment Progress".
-
Br J Cancer: A new risk stratification prediction model for diffuse large B-cell lymphoma DLBCL
Time of Update: 2021-05-31
The study established and verified an accurate predictive model, which is better than the IPI model and NCCN-IPI model for the prognostic stratification of DLBCL patients.
The study established and verified an accurate predictive model, which is better than the IPI model and NCCN-IPI model for the prognostic stratification of DLBCL patients.
-
Diffuse large B-cell lymphoma requires clear factors and efficacy evaluation before treatment
Time of Update: 2021-04-28
In addition, the PET/CT assessment results of DLBCL patients after 2 to 4 cycles of treatment may affect the patient's prognosis.
Therefore, it is not recommended to guide the follow-up treatment of DLBCL based on the results of mid-term PET/CT evaluation outside of clinical trials.
-
Cooperation | Jingtai Technology joins hands with Sigma Biosciences to promote major progress in the diffuse gastric cancer project
Time of Update: 2021-04-18
In the specific research and development process of this diffuse gastric cancer target project, Jingtai Technology first used the self-developed artificial intelligence drug discovery platform (ID4 platform) to generate millions of compound molecules, and through AI technology and high-precision computational chemistry tools, Calculate and evaluate the various properties of the generated molecules (such as activity, selectivity, drug-like properties, novelty, synthesizable, etc.
-
J Clin Invest: H3.3K27M specific vaccine response in diffuse midline glioma
Time of Update: 2021-04-17
3K27M targeted peptide vaccine, and the results have been published in J Clin Invest.
3K27M-specific vaccine responses in diffuse midline gliom .
3K27M-specific vaccine responses in diffuse midline gliom in this message
-
Progress in the treatment of newly diagnosed diffuse large B-cell lymphoma
Time of Update: 2021-04-14
The results of a phase II clinical trial showed that [11], newly diagnosed patients with limited-stage DLBCL can achieve CMR after only 3 cycles of R-CHOP treatment, using PET/CT assessment.
-
Progress in the treatment of relapsed or refractory diffuse large B-cell lymphoma
Time of Update: 2021-04-14
This article aims to summarize the treatment progress of patients with relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL) in recent years for your reference.
-
Diffuse large B-cell lymphoma requires clear factors and efficacy evaluation before treatment
Time of Update: 2021-03-27
In addition, the PET/CT assessment results of DLBCL patients after 2 to 4 cycles of treatment may affect the patient's prognosis.
Therefore, it is not recommended to guide the follow-up treatment of DLBCL based on the results of mid-term PET/CT evaluation outside of clinical trials.
-
NEJM review: diffuse large B-cell lymphoma (pictured: new drugs, treatment processes, prognosis, molecular division)
Time of Update: 2021-03-23
In the past 20 years, we have gained in-depth understanding of the epidemiology, prognostic factors, and biological heterogeneity of large B-cell lymphoma, improved the classification of diseases, and developed new therapies.
-
Eur Radiol: Feasibility study of MRI-guided breast biopsy based on diffusion-weighted imaging
Time of Update: 2021-03-19
We identified 64 of 87 operations that can detect lesions in DWI; added DWI sequences to the standard protocol to locate lesions and biopsy devices, and evaluate the correct location of site markers.
-
Clinical Nutrition: The bioavailability of 25(OH)D is related to the clinical outcome of patients with diffuse large B-cell lymphoma
Time of Update: 2021-03-19
Therefore, here, this study aims to determine the prognostic value of circulating total 25(OH)D and bioavailability 25(OH)D levels in patients with diffuse large B-cell lymphoma (DLBCL) in patients with DLBCL.
-
JCO: The treatment of rhonamide combined with R-CHOP can prolong the survival of patients with untreated diffuse large B-cell lymphoma
Time of Update: 2021-02-25
For untreated patients with diffuse large B-cell lymphoma (DLBCL) (including COO and ABC-DLBCL subtypes), the Synadamic Unilidoxi monoantigen-cyclophosphamide-dorobi-star-changchun-neo-alkali-pernisson (R-CHOP) program (R2CHOP) can extend its lifetime.
overall, ECOG-ACRIN E1412 studies have shown potential clinical benefits of adding amine to R-CHOP in the future in newly diagnosed patients, including COO and ABC-DLBCL patients.
-
Nat Commun: Dual target polyamine synthesis and ingestion: a potential treatment strategy for diffuse endogenetic brain bridge glioma
Time of Update: 2021-02-24
studies have shown that DIPG cells can compensate for the inhibition of ODC1 by raising the expression of the polyamine transport protein SLC3A2.
-
Chinese scientists have led the construction of a map of the origin and diffusion of the global
Time of Update: 2021-02-23
17th, Nature-Communication published online the latest research results of Lin Qiang, a researcher at the South China Sea Oceanographic Research Institute of the Chinese Academy of Sciences, in coope
-
Lancet Haematol: The MATRix-RICE program is effective in treating secondary CNS-soaked diffuse large B-cell lymphoma in a joint self-bodies HSCT
Time of Update: 2021-02-10
treatment with MATRix-RICE, 49 patients (65 percent; 95 percent CI 54-76) received objective remission, of which 29 (39 percent) were fully relieved.
at the end of the programme, 46 patients (61 per cent; 95 per cent CI 51-71) received objective remission with a medium duration of 26 months (IQR 16-37).